These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23875873)

  • 1. Clinical utility and cost of non-invasive prenatal testing.
    Cuckle H; Benn P; Pergament E
    J Matern Fetal Neonatal Med; 2014 Feb; 27(3):320-1. PubMed ID: 23875873
    [No Abstract]   [Full Text] [Related]  

  • 2. Author response to letter from Song et al.
    Song K; Musci T; Caughey AB
    J Matern Fetal Neonatal Med; 2014 Jun; 27(9):972. PubMed ID: 24007257
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population.
    Song K; Musci TJ; Caughey AB
    J Matern Fetal Neonatal Med; 2013 Aug; 26(12):1180-5. PubMed ID: 23356557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness and accuracy of prenatal Down syndrome screening strategies: should the combined test continue to be widely used?
    Gekas J; Durand A; Bujold E; Vallée M; Forest JC; Rousseau F; Reinharz D
    Am J Obstet Gynecol; 2011 Feb; 204(2):175.e1-8. PubMed ID: 21074138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-natal screening for Down's syndrome.
    Phillips A; Wakeman A
    J Public Health Med; 1994 Mar; 16(1):114-5; author reply 116-7. PubMed ID: 8080557
    [No Abstract]   [Full Text] [Related]  

  • 6. Concerns following rapid implementation of first-line screening for aneuploidy by cell-free DNA analysis in the Belgian healthcare system.
    Abousleiman C; Lismonde A; Jani JC
    Ultrasound Obstet Gynecol; 2019 Jun; 53(6):847-848. PubMed ID: 30937993
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of Down syndrome screening paradigms.
    Caughey AB; Kaimal AJ; Odibo AO
    Clin Lab Med; 2010 Sep; 30(3):629-42. PubMed ID: 20638577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of maternal age on the cost effectiveness of Down's syndrome screening.
    Torgerson DJ
    Br J Obstet Gynaecol; 1996 Jun; 103(6):581-3. PubMed ID: 8645654
    [No Abstract]   [Full Text] [Related]  

  • 9. Economic analysis of prenatal screening strategies for Down syndrome in singleton pregnancies in Turkey.
    Ökem ZG; Örgül G; Kasnakoglu BT; Çakar M; Beksaç MS
    Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():40-44. PubMed ID: 29040895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What will be the role of first-trimester ultrasound if cell-free DNA screening for aneuploidy becomes routine?
    Sonek JD; Cuckle HS
    Ultrasound Obstet Gynecol; 2014 Dec; 44(6):621-30. PubMed ID: 25449114
    [No Abstract]   [Full Text] [Related]  

  • 11. Integrated, sequential, and contingent screening for Down syndrome - local needs should drive methodology.
    Wyatt P
    Prenat Diagn; 2007 Feb; 27(2):186-7. PubMed ID: 17266162
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness and Down syndrome.
    Ganiats TG; Cantor SB
    Am J Public Health; 1999 Jan; 89(1):110-2. PubMed ID: 9987481
    [No Abstract]   [Full Text] [Related]  

  • 13. Screening for Down's syndrome. Costings are crucial to model.
    Whittle M
    BMJ; 2002 Jan; 324(7329):111. PubMed ID: 11808521
    [No Abstract]   [Full Text] [Related]  

  • 14. [Serum analysis in pregnant women. Mass screening is an effective way to discover chromosome aberrations--arguments for and against].
    Kristoffersson U; Nørgaard-Pedersen B
    Lakartidningen; 1995 Mar; 92(12):1205-6, 1211-2. PubMed ID: 7535873
    [No Abstract]   [Full Text] [Related]  

  • 15. [Non-invasive prenatal testing is a breakthrough in prenatal screening].
    Hornstrup LS; Ambye L; Sørensen S; Jørgensen FS
    Ugeskr Laeger; 2015 Jul; 177(28):. PubMed ID: 26239855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome.
    Walker BS; Jackson BR; LaGrave D; Ashwood ER; Schmidt RL
    Prenat Diagn; 2015 May; 35(5):440-6. PubMed ID: 25273838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost utility of prenatal diagnosis.
    Bradbury I; Wright D; Slattery J; Ritchie K
    Lancet; 2004 Apr; 363(9415):1164-5; author reply 1165. PubMed ID: 15064048
    [No Abstract]   [Full Text] [Related]  

  • 18. Marginal costs and benefits.
    Torgerson DJ; Spencer A
    BMJ; 1996 Jan; 312(7022):35-6. PubMed ID: 8555859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The price of performance: a cost and performance analysis of the implementation of cell-free fetal DNA testing for Down syndrome in Ontario, Canada.
    Okun N; Teitelbaum M; Huang T; Dewa CS; Hoch JS
    Prenat Diagn; 2014 Apr; 34(4):350-6. PubMed ID: 24395030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-benefit analysis of prenatal diagnosis for Down syndrome using the British or the American approach.
    Walker M; Pandya P
    Obstet Gynecol; 2000 Sep; 96(3):481. PubMed ID: 11001699
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.